HUTCHMED (China) Management

Management criteria checks 4/4

HUTCHMED (China)'s CEO is Wei-Guo Su, appointed in Jan 2012, has a tenure of 12.25 years. total yearly compensation is $2.45M, comprised of 32.5% salary and 67.5% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth £12.14M. The average tenure of the management team and the board of directors is 10.6 years and 7.2 years respectively.

Key information

Wei-Guo Su

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage	32.5%
CEO tenure	12.3yrs
CEO ownership	0.5%
Management average tenure	10.6yrs
Board average tenure	7.2yrs

Recent management updates

Recent updates

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

Apr 04

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Mar 14

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

Mar 01

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Apr 19

CEO Compensation Analysis

How has Wei-Guo Su's remuneration changed compared to HUTCHMED (China)'s earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$798k	US$101m
Sep 30 2023	n/a	n/a	US$36m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$195m
Dec 31 2022	US$4m	US$700k	-US$361m
Sep 30 2022	n/a	n/a	-US$308m
Jun 30 2022	n/a	n/a	-US$255m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$3m	US$395k	-US$195m
Sep 30 2021	n/a	n/a	-US$187m
Jun 30 2021	n/a	n/a	-US$178m
Mar 31 2021	n/a	n/a	-US$151m
Dec 31 2020	US$1m	US$346k	-US$126m
Sep 30 2020	n/a	n/a	-US$117m
Jun 30 2020	n/a	n/a	-US$110m
Mar 31 2020	n/a	n/a	-US$102m
Dec 31 2019	US$1m	US$274k	-US$106m
Sep 30 2019	n/a	n/a	-US$93m
Jun 30 2019	n/a	n/a	-US$87m
Mar 31 2019	n/a	n/a	-US$83m
Dec 31 2018	US$1m	US$273k	-US$75m
Sep 30 2018	n/a	n/a	-US$72m
Jun 30 2018	n/a	n/a	-US$61m
Mar 31 2018	n/a	n/a	-US$39m
Dec 31 2017	US$2m	US$310k	-US$27m

Compensation vs Market: Wei-Guo's total compensation ($USD2.45M) is about average for companies of similar size in the UK market ($USD2.58M).

Compensation vs Earnings: Wei-Guo's compensation has been consistent with company performance over the past year.

CEO

Wei-Guo Su (65 yo)

12.3yrs

Tenure

US$2,451,164

Compensation

Dr. Wei-Guo Su, B.Sc., Ph D., has been the Chief Executive Officer of HUTCHMED (China) Limited since March 04, 2022. Dr. Su has been the Chief Scientific Officer and Executive Vice President of HUTCHMED (C...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Chi Keung To	Executive Chairman	24.3yrs	US$85.00k	0.29% $ 7.2m
Wei-Guo Su	CEO, Chief Scientific Officer & Executive Director	12.3yrs	US$2.45m	0.49% $ 12.1m
Chig Fung Cheng	CFO & Executive Director	15.8yrs	US$962.15k	0.18% $ 4.5m
Edith Shih	Company Secretary & Non-Executive Director	18.3yrs	no data	0.14% $ 3.5m
Karen Jane Atkin	Executive VP & COO	3.3yrs	no data	no data
David Ng	Head of Investor Relations & Capital Strategies	no data	no data	no data
Charles George Rupert Nixon	Group General Counsel	8.9yrs	no data	no data
Kin Hung Lee	Senior Vice President of Corporate Management & Communications	1.3yrs	no data	no data
Selina Zhang	Senior Vice President of Global Human Resources	2.3yrs	no data	no data
Qingmei Wang	Senior Vice President of Business Development & Strategic Alliances	no data	no data	no data
Hong Chen	Senior VP & Chief Commercial Officer- China	6.3yrs	no data	no data
Zhenping Wu	Executive Vice President of Pharmaceutical Science & Manufacturing	12.3yrs	no data	no data

10.6yrs

Average Tenure

58.5yo

Average Age

Experienced Management: HCM's management team is seasoned and experienced (10.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Chi Keung To	Executive Chairman	24.3yrs	US$85.00k	0.29% $ 7.2m
Wei-Guo Su	CEO, Chief Scientific Officer & Executive Director	7.1yrs	US$2.45m	0.49% $ 12.1m
Chig Fung Cheng	CFO & Executive Director	13.3yrs	US$962.15k	0.18% $ 4.5m
Edith Shih	Company Secretary & Non-Executive Director	18.3yrs	no data	0.14% $ 3.5m
Dan Eldar	Non-Executive Director	7.7yrs	no data	0.013% $ 317.9k
Ling Yang	Non-Executive Director	less than a year	no data	no data
Graeme Allan Jack	Independent Non-Executive Director	7.1yrs	US$250.00k	0.0053% $ 132.4k
Paul Rutherford Carter	Senior Independent Non-Executive Director	7.2yrs	US$117.00k	0.0087% $ 214.6k
Shu Kam Mok	Independent Non-Executive Director	6.5yrs	US$114.86k	0.011% $ 277.3k

7.2yrs

Average Tenure

65yo

Average Age

Experienced Board: HCM's board of directors are considered experienced (7.2 years average tenure).

HUTCHMED (China) Management

Management criteria checks 4/4

Key information

Recent management updates

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

Key Executive exercised options to buy UK£6.7m worth of stock.

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

CFO & Executive Director recently sold UK£2.4m worth of stock

Less than half of directors are independent

Recent updates

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 19%

The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Consensus revenue estimates decrease by 18%

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0102 profit

New minor risk - Share price stability

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED (China) (LON:HCM) Is Using Debt Safely

Consensus EPS estimates increase from loss to US$0.0051 profit

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates increase from loss to US$0.0016 profit

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Consensus EPS estimates upgraded to US$0.0045 loss

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet?

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

Key Executive exercised options to buy UK£6.7m worth of stock.

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

Consensus estimates of losses per share improve by 42%

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Consensus EPS estimates upgraded to US$0.25 loss

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Is HUTCHMED (China) (LON:HCM) A Risky Investment?

With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

CFO & Executive Director recently sold UK£2.4m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021)

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

Less than half of directors are independent

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

Now 21% undervalued after recent price drop

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Now 23% undervalued after recent price drop

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Inmagene Biopharmaceuticals and HUTCHMED (China) Limited Announce First Participant in Global Phase I Trial of IMG-004

HUTCHMED (China) Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic Colorectal Cancer

First half 2022 earnings released

HUTCHMED (China) Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China